

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

In Reply Please Refer To The Following: EXAMINER'S NAME J F Niebling			Paper No5/B
GR. ART UN.	FILING DATE	SERIAL NO.	
Werner Bollag			Mailed
AP	PLICANT	INVENTION	
POLYENE COMPOUNDS			18

Jon S. Saxe
340 Kingsland St.
Mutley, N.J. 07110

MAILED
NOV 14 1979
CROUP 110

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents and Trademarks

CHANGES AND/OR ADDITIONS TO THE APPLICATION RECORD MADE BY THE EXAMINER UPON ALLOWANCE

This application is in condition for allowance and the following changes have been made therein by the Examiner. Should the changes be unacceptable to applicant, an appropriate amendment may be proposed <u>after the Notice of Allowance has been received</u>, as provided under Rule 312. To ensure consideration of such an amendment, it must be submitted on or before remittance of the Base Issue Fee.

PROSECUTION ON THE MERITS IS CLOSED. A NOTICE OF ALLOWANCE WILL BE MAILED IN DUE COURSE.

[] Note attached Notice of References Cited PTO892, which is part of this communication. The listed references are considered to be pertinent to the claimed invention, but the claims are deemed patentable thereover.

In accordance with a telephone communication with Mr. Johnston on October 22 and November 1, 1979, the following changes have been authorized

amend:title to read

-- 9 Phenyl-Nonate traene Compounds-Cancel Claims I to 29.

These claims have been cancelled as the non-elected invention under the following restriction under 35 USC 121:

Serial No. 55,437 Art Unit 117

- I. Claims 1 to 25 phosphonium compounds; Class 260-606.5 F.
- II. Claims 26 and 27, phosphorous esters, Class 260-290+
- III. Claims 28 and 29, sulphone compounds,
 Class 260-502.6+
 - IV. Claims 40 to 75 phenyl tetraene; 260-404+

These inventions represent separate and distinct Classes of Chemical compounds having unique Chemical and Physical properties. The Claims are allowable because these types of compounds are not disclosed in the prior art wherein the phenyl ring always contains a lower alway moiety; also, given applicants' utility as anti-tumor agents, it would not have been obvious from the prior art compounds to make this substitution.

Receipt is acknowledged of papers submitted under 35 USC 119, which papers have been made of record in the parent cases SN's. 454,007 and 601, 148.

JOHN F. NIEBLING
PRIMARY EXAMINER
GROUP ART UNIT 117

JFNiebling:ebm 703-557-3591 11/5/79